Page 384 - Binder2

escalation, they orchestrate a tightly managed regimen
designed to balance efficacy, safety, and adherence. This
model made sense when biologics were high-risk
interventions—fragile proteins requiring cold-chain
storage, injectable delivery, and regular immune
monitoring. For these therapies, physician oversight wasn’t
optional. It was essential.

But what happens when the biologic becomes a capsule?

What happens when the treatment is shelf-stable, orally
administered, and grown in a greenhouse instead of
manufactured in a cleanroom?

What happens when the patient no longer needs a hospital
bed—but a refrigerator shelf?

The answer isn’t that doctors become irrelevant. It’s that
their role shifts—from procedural managers to longitudinal
partners. From prescribers of a fragile drug to stewards of a
durable, immune-compatible therapy.

From Supervisor to Strategist

In the current infusion-centered paradigm, the physician’s
role in biologic therapy is largely procedural. They are the
coordinator of a tightly choreographed dance:

• Coordinating infusion schedules with hospital
systems or outpatient centers.
• Ordering lab panels to monitor biomarkers and
screen for infection risk.

382